Overview
Cytokeratin 5 (CK5) and Cytokeratin 6 (CK6) are basic (type II) cytokeratins with molecular weights of approximately 58 kDa (CK5) and 56 kDa (CK6). Commonly used antibodies target both CK5 and CK6 together. CK5 pairs primarily with CK14, while CK6 pairs with CK16 or CK17. CK5 can also be detected using high–molecular-weight cytokeratin antibodies such as 34βE12 (K903) and pan-cytokeratin markers like AE1/AE3.
CK5/6 is classified as a basal cytokeratin and is normally expressed in squamous epithelium. Its expression is retained in squamous cell carcinoma, making it a key immunohistochemical marker for basal and squamous differentiation. CK56-and-CK5.pptx
Symptoms
CK5/6 itself does not cause symptoms. Its clinical importance lies in the evaluation of tumors where patients present with symptoms related to malignancies of the lung, pleura, breast, prostate, bladder, or skin. CK5/6 expression assists in linking histopathological findings with clinical suspicion, particularly in cases where pleural mesothelioma may be misdiagnosed as lung cancer.
CK5/6 expression reflects basal or squamous epithelial differentiation. Cytokeratin 5/6 is a positive marker for malignant pleural mesothelioma, being expressed in more than three-fourths of cases. It is also expressed in certain types of lung and breast cancers.
CK5/6 antibodies are widely used to identify basal cells or myoepithelial cells in prostate and breast tissue, especially for assessing invasion. They help rule out invasive carcinoma in breast and prostate biopsies. When used in combination with p63, CK5/6 aids in detecting squamous cell origin in poorly differentiated carcinomas.
Additionally, CK5/6 helps distinguish epithelioid mesothelioma (usually CK5/6 positive) from lung adenocarcinoma (usually CK5/6 negative). In breast pathology, CK5/6 is useful in differentiating benign proliferative lesions (which show a mosaic-like staining pattern) from ductal carcinoma in situ (DCIS), which is predominantly negative or rarely diffusely positive. Risk Factors
CK5/6 expression carries diagnostic and prognostic implications. In pleural effusions, CK5/6 positivity supports a diagnosis of mesothelioma, whereas negativity favors lung adenocarcinoma. In bladder pathology, full-thickness CK5/6 staining is seen in condyloma acuminatum, while patchy staining is observed in papillary non-invasive urothelial carcinoma.
CK5/6 immunostaining has also been proposed to have prognostic utility in triple-negative breast cancer, urothelial carcinoma, and other tumors. In Grade III breast carcinoma, CK5/6 positivity indicates a basal-like molecular phenotype, which is associated with poor prognosis. Patients with this subtype are recommended for BRCA1 mutation testing, highlighting the role of CK5/6 in guiding further genetic evaluation and risk assessment.
Prevention
There is no direct prevention related to CK5/6 expression, as it is a diagnostic biomarker rather than a disease. Accurate diagnosis depends on the proper immunohistochemical technique. CK5/6 testing is performed on formalin-fixed, paraffin-embedded tissue.
CK5/6 typically shows diffuse cytoplasmic staining with perinuclear enhancement. Positive control tissues known to express CK5/6 are essential to validate staining reliability.
When included as part of an immunohistochemical panel alongside AE1/AE3 and myoepithelial markers, CK5/6 improves differentiation between benign and malignant breast lesions, particularly in cases with interobserver variability. Through correct interpretation, CK5/6 contributes to accurate diagnosis, prognostic stratification, and selection of appropriate treatment modalities.
